Human Vaccines & Immunotherapeutics (May 2017)

BCG and Kawasaki disease in Mexico and Japan

  • Luisa Berenise Gamez-Gonzalez,
  • Hiromichi Hamada,
  • Beatriz Adriana Llamas-Guillen,
  • Miguel Ruiz-Fernandez,
  • Marco Yamazaki-Nakashimada

DOI
https://doi.org/10.1080/21645515.2016.1267083
Journal volume & issue
Vol. 13, no. 5
pp. 1091 – 1093

Abstract

Read online

Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30–50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently, Yamada et al. reported a severe BCG reaction with tuberculid in 2 Japanese KD patients. We present 2 cases with KD and severe BCG reaction, one from Japan and the other from Mexico and review the policies of administration of BCG in both countries. The BCG vaccine has a worldwide coverage of 88%. Differences in BCG strains and methods of administration may influence BCG reactions in KD. The BCG reaction in the inoculation site may represent the most useful sign in KD.

Keywords